Molecular Partners Unveils Promising MP0712 Data at TRP Summit

An announcement from Molecular Partners ( (MOLN) ) is now available.

On November 12, 2025, Molecular Partners presented new data on its lead Radio-DARPin, MP0712, targeting DLL3 at the TRP Summit Europe. The data included initial human images showing specific uptake in primary tumors and metastatic lesions, supporting the mechanism of action. The company is preparing for a Phase 1 trial in the US by the end of 2025, with initial data expected in 2026. This development marks a significant milestone in the clinical advancement of MP0712, potentially impacting the treatment of small cell lung cancer and other neuroendocrine cancers.

The most recent analyst rating on (MOLN) stock is a Hold with a $4.50 price target. To see the full list of analyst forecasts on Molecular Partners stock, see the MOLN Stock Forecast page.

Spark’s Take on MOLN Stock

According to Spark, TipRanks’ AI Analyst, MOLN is a Neutral.

The overall stock score of 51 reflects significant financial challenges, including declining revenue and negative profitability margins, which are partially offset by positive technical indicators suggesting short-term bullish momentum. The negative P/E ratio and lack of dividend yield further weigh on the valuation.

To see Spark’s full report on MOLN stock, click here.

More about Molecular Partners

Molecular Partners AG is a clinical-stage biotech company specializing in the development of DARPin therapeutics, a new class of protein drugs designed to address medical challenges that other drug modalities cannot easily tackle. The company focuses primarily on oncology and leverages its proprietary DARPin platform to create unique solutions for patients, collaborating with leading pharmaceutical companies.

Average Trading Volume: 5,438

Technical Sentiment Signal: Hold

Current Market Cap: $165.9M

For a thorough assessment of MOLN stock, go to TipRanks’ Stock Analysis page.